Home / Middle East / Oman / Life Sciences & Healthcare

Life Sciences & Healthcare

We work with and have established long-term relationships with the top 100 life sciences and healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies. Our life sciences and healthcare experts across the Middle East advise leading global business groups in the sector on transactions, commercial agreements, compliance, investigations and litigation, very often across multiple jurisdictions in the region and beyond. We can help you to navigate the regulatory landscape and to ensure compliance with both local laws and global policies.

With over 480 international specialist lawyers across CMS, we understand the scientific and commercial as well as the legal imperatives affecting your life sciences and healthcare business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences and healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice.

Feed

01/06/2022
CMS Next
What’s next? In a world of ever-ac­cel­er­at­ing change, stay­ing ahead of the curve and know­ing what’s next for your busi­ness or sec­tor is es­sen­tial.At CMS, we see ourselves not only as your leg­al ad­visers but also as your busi­ness part­ners. We work to­geth­er with you to not only re­solve cur­rent is­sues but to an­ti­cip­ate fu­ture chal­lenges and in­nov­ate to meet them.With our latest pub­lic­a­tion, CMS Next, our ex­perts will reg­u­larly of­fer you in­sights in­to and fresh per­spect­ives on a range of is­sues that busi­nesses have to deal with – from ESG agen­das to re­struc­tur­ing after the pan­dem­ic or fa­cing the di­git­al trans­form­a­tion. We will also share with you more about the work that we are do­ing for our cli­ents, help­ing them in­nov­ate, grow and mit­ig­ate risk.To be able to provide you with the best sup­port, we im­merse ourselves in your world to un­der­stand your leg­al needs and chal­lenges. However, it is equally im­port­ant that you know who we are and how we can work with you. So, we in­vite you to meet our ex­perts and catch a glimpse of what is hap­pen­ing in­side CMS.En­joy read­ing this pub­lic­a­tion, which we will up­date reg­u­larly with new con­tent.CMS Ex­ec­ut­ive Team
24/11/2021
On the Pulse
Wel­come to CMS ‘On the Pulse’ video/pod­cast series for all Life Sci­ences & Health­care pro­fes­sion­als – leg­al, com­pli­ance, reg­u­lat­ory
03/06/2021
The in­tro­duc­tion of VAT in the Sul­tan­ate of Oman: a brief leg­al guide
GCC mem­ber states all signed up to the GCC-Wide VAT Agree­ment in 2016, which serves as a guide for gulf coun­cil states to im­ple­ment al­most identic­al, do­mest­ic value ad­ded tax (VAT) laws in the sup­ply...
01/06/2021
Some leaks can­'t be fixed
“Con­fid­en­tial in­form­a­tion is like an ice cube... give it to the party who has no re­fri­ger­at­or or will not agree to keep it in one, and by the time of the tri­al you have just a pool of wa­ter.” This...
23/03/2021
The En­larged Board of the European Pat­ent Of­fice has giv­en a mo­ment­ous...
The En­larged Board of the European Pat­ent Of­fice heard or­al ar­gu­ments in Ju­ly 2020 con­cern­ing pat­entab­il­ity of a com­puter soft­ware in­ven­tion.  This rare event was video streamed to over 1600 pat­ent stake­hold­ers...
28/09/2020
High Court con­firms that the class of in­ven­tions cre­ated by AI ma­chines...
The High Court has con­firmed that the class of in­ven­tions cre­ated by AI ma­chines is not pat­entable. The de­cision po­ten­tially leaves the door open for hu­man own­ers of AI ma­chines to list them­selves as...
13/08/2020
Sus­tain­able food pro­gress may close glob­al reg­u­lat­ory gap
In­nov­a­tion in the sus­tain­able food sec­tor is for­ging ahead at a re­mark­able pace. Our cur­rent food sources ac­count for nearly one-third of glob­al GHG emis­sions while con­sumers are in­creas­ingly bet­ter edu­cated...
08/07/2020
“WIPO PROOF”: WIPO’s new on­line ser­vice which helps in­nov­at­ors and cre­at­ors...
The World In­tel­lec­tu­al Prop­erty Or­gan­isa­tion (WIPO) re­cently launched its new on­line busi­ness ser­vice, “WIPO PROOF”. The plat­form aims to help in­nov­at­ors and cre­at­ors safe­guard their in­tel­lec­tu­al...
22/05/2020
For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
11/05/2020
AI in Life Sci­ences
Ar­ti­fi­cial in­tel­li­gence is not new: the term it­self was coined over 60 years ago. However, the con­ver­gence of data volume, pro­cessing power and tech­nic­al cap­ab­il­ity has con­vinced many that the AI era...
04/05/2020
EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
30/04/2020
USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...